First Report of Inclisiran Utilization for Hypercholesterolemia Treatment in Real-world Clinical Settings in a Middle East Population-Reference-Cited by-同舟云学术

First Report of Inclisiran Utilization for Hypercholesterolemia Treatment in Real-world Clinical Settings in a Middle East Population

Published:2024-03 Issue:3 Volume:46 Page:186-193
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Iqbal Sajid,Sabbour Hani Mohamed,Ashraf Tanveer,Santos Raul D.,Buckley Adam

Funder

Imperial College London Diabetes Centre

Publisher

Elsevier BV

Reference36 articles.

1. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;Eur Heart J,2017

2. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study;Koren;J Am Coll Cardiol,2004

3. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial;Giugliano;Lancet,2017

4. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants;Wang;Lancet Diabetes Endocrinol,2020

5. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease;Sabatine;N Engl J Med,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipid-lowering therapy with inclisiran in the real-world setting: Initial data from a national health care service;Journal of Clinical Lipidology;2024-05